Novartis AG (NVS)
NVS moved a median of +0.03% 30 minutes after news, and -0.09% by the close. How NVS actually reacts to news — the realized, point-in-time move the market made, measured across 326 labeled events over the last three years with zero look-ahead.
NVS’s median reaction, across the day.
| Horizon | Median | % positive | Events |
|---|---|---|---|
| 5-min | 0.00% | 50% | 325 |
| 30-min | +0.03% | 51% | 325 |
| 60-min | +0.04% | 54% | 325 |
| to close | -0.09% | 45% | 322 |
| Middle 50% of NVS reactions | -0.19% to +0.24% |
|---|---|
| Median reaction (30-min) | +0.03% |
| Measured reactions | 326 |
Half of all Novartis AG news events land between -0.19% and +0.24% at 30 minutes.
Reaction stats as of 2026-09-21. Newest measured event . Reaction = percent move vs. the price at the news timestamp.
How NVS reacts, by analyst action.
| Event | Events | Median 30-min | % positive | Median to close |
|---|---|---|---|---|
| Analyst upgrades | 20 | +0.03% | 55% | +0.27% |
| Analyst downgrades | 15 | -0.31% | 20% | -0.43% |
| Coverage initiations | 14 | -0.09% | 43% | +0.28% |
| Rating reiterations | 26 | 0.00% | 39% | +0.06% |
Last 3 years, pulled 2026-09-21. Reaction = percent move vs. the price at the news timestamp. Counts and medians only. The same measurement runs across every name in the dataset. 1 further class was observed with fewer than 10 measured events and is not published. See how NVS ranks against every other measured name →
That’s how NVS usually reacts — get an email when it moves on news →Email me when NVS moves on news.
One email per qualifying move — the headline, the measured reaction, and how it compares to NVS's baseline. Nothing else.
Recent NVS events, each with its measured reaction.
| Date | Headline | Event | Source | 5-min | To close |
|---|---|---|---|---|---|
| Bronstein, Gewirtz & Grossman, LLC Encourages Novartis AG (NVS) Shareholders to Inquire about Securities Investigation | Press release | ACCESS Newswire | +0.04% | +0.23% | |
| Bronstein, Gewirtz & Grossman, LLC Is Investigating Novartis AG (NVS) And Encourages Shareholders to Connect | Press release | ACCESS Newswire | +0.04% | +0.35% | |
| Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Novartis AG (NVS) And Encourages Shareholders to Reach Out | Press release | ACCESS Newswire | +0.11% | +0.03% | |
| Bronstein, Gewirtz & Grossman, LLC Encourages Novartis AG (NVS) Stockholders to Inquire about Securities Investigation | Press release | ACCESS Newswire | -0.01% | +0.23% | |
| Novartis AG (NVS) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation | Press release | ACCESS Newswire | -0.32% | -0.65% | |
| Bronstein, Gewirtz & Grossman, LLC Encourages Novartis AG (NVS) Stockholders to Inquire about Securities Investigation | Press release | ACCESS Newswire | -0.14% | +0.21% | |
| Bronstein, Gewirtz & Grossman, LLC Encourages Novartis AG (NVS) Investors to Inquire about Securities Investigation | Press release | ACCESS Newswire | -0.11% | -0.46% | |
| Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Novartis AG (NVS) And Encourages Stockholders to Reach Out | Press release | ACCESS Newswire | +0.00% | -0.68% | |
| Bronstein, Gewirtz & Grossman, LLC Is Investigating Novartis AG (NVS) And Encourages Stockholders to Connect | Press release | ACCESS Newswire | -0.03% | -0.32% | |
| Form 6-K NOVARTIS AG For: Sep 08 | SEC filing · Form 6-K | SEC EDGAR | +0.43% | -1.25% | |
| Form 6-K NOVARTIS AG For: Sep 04 | SEC filing · Form 6-K | SEC EDGAR | +0.43% | -1.25% | |
| Form 6-K NOVARTIS AG For: Sep 01 | SEC filing · Form 6-K | SEC EDGAR | +0.38% | -0.56% | |
| Novartis receives Health Canada approval for (Pr)RHAPSIDO® (remibrutinib tablets) oral treatment for adults with CSU | Press release | Canada Newswire | -0.06% | -0.34% | |
| Form 6-K NOVARTIS AG For: Jun 30 | SEC filing · Form 6-K | SEC EDGAR | -2.64% | -3.41% | |
| Novartis receives Health Canada approval for VANRAFIA™ (atrasentan tablet) for proteinuria reduction in adults with primary immunoglobulin A nephropathy (IgAN) | Press release | Canada Newswire | +0.07% | +0.00% | |
| datosX Launches SIGNAL, the AI-Enabled Platform Helping Digital Health + AI Companies Validate and Build Commercial Traction with U.S. Health Systems | Press release | PR Web | -0.14% | -1.04% | |
| Novartis Canada and SP Quebec Celebrate 16 Years of Partnership Through Annual MS Tri-Challenge Fundraiser | Press release | Canada Newswire | -0.05% | +0.28% | |
| Form 6-K NOVARTIS AG For: Jun 11 | SEC filing · Form 6-K | SEC EDGAR | +0.14% | +1.26% | |
| Novartis Canada and the pan-Canadian Pharmaceutical Alliance Achieve Milestone Agreement Enabling Public Reimbursement of (pr)Scemblix® (asciminib tablets) | Press release | Canada Newswire | -0.06% | +0.14% | |
| Novartis Canada Recognizes Next Generation of Oncology Innovators Through NOYCIA Awards at ASCO | Press release | Canada Newswire | -0.01% | -0.16% | |
| Novartis Canada Recognizes MS Awareness Month with the Third Annual My Krew Campaign | Press release | Canada Newswire | +0.01% | -0.14% | |
| Novartis receives Health Canada approval for Fabhalta® oral treatment for adults with C3G | Press release | Canada Newswire | +0.07% | -0.22% | |
| Form 6-K NOVARTIS AG For: Mar 31 | SEC filing · Form 6-K | SEC EDGAR | -0.76% | +0.86% | |
| Novartis malaria treatment Coartem® Baby receives WHO prequalification, paving way for greater access for newborns and young infants | Press release | GlobeNewswire | -0.29% | -0.38% | |
| Novartis announces expansion of community health programs to close gaps in heart disease and cancer care, targeting more than 30 countries by 2030 | Press release | GlobeNewswire | +0.11% | +1.42% | |
| Novartis Canada Reopens NOYCIA 2026, Continuing Its Longstanding Investment in the Future of Oncology Research | Press release | Canada Newswire | +0.07% | +0.02% | |
| Form 6-K NOVARTIS AG For: Mar 18 | SEC filing · Form 6-K | SEC EDGAR | +0.15% | +0.02% | |
| Kisqali® Receives Positive Draft Recommendation From Canada's Drug Agency For All Eligible Early Breast Cancer Patients at High Risk of Recurrence | Press release | Canada Newswire | +0.40% | +1.54% | |
| Form 20-F NOVARTIS AG For: Dec 31 | SEC filing · Form 20-F | SEC EDGAR | -0.35% | -1.13% | |
| Form 6-K NOVARTIS AG For: Dec 31 | SEC filing · Form 6-K | SEC EDGAR | -0.35% | -1.13% | |
| Form IRANNOTICE NOVARTIS AG | SEC filing · Form IRANNOTICE | SEC EDGAR | -0.35% | -1.13% | |
| Form S-8 NOVARTIS AG | SEC filing · Form S-8 | SEC EDGAR | +0.41% | +1.28% | |
| NFL Greats and Novartis Tackle Prostate Cancer Myths at Super Bowl LX: "Relax, It's a Blood Test" | Press release | PR Newswire | -0.01% | +0.11% | |
| Form S-8 POS NOVARTIS AG | SEC filing · Form S-8 | SEC EDGAR | -0.74% | -0.29% | |
| Novartis to add radioligand therapy manufacturing facility in Winter Park, Florida, fourth in US to serve patients and advance $23 billion investment | Press release | GlobeNewswire | -0.08% | -0.80% | |
| Novartis breaks ground on flagship manufacturing hub in North Carolina | Press release | GlobeNewswire | +0.21% | +0.15% | |
| Scemblix® Receives Priority Access in Ontario Under New FAST Program | Press release | Canada Newswire | -0.02% | +0.11% | |
| High-risk Early Breast Cancer Patients in Quebec Left Behind by Recent INESSS Recommendation | Press release | Canada Newswire | +0.01% | -0.90% | |
| Form 6-K NOVARTIS AG For: Nov 24 | SEC filing · Form 6-K | SEC EDGAR | +0.49% | +1.17% | |
| Form 6-K NOVARTIS AG For: Nov 20 | SEC filing · Form 6-K | SEC EDGAR | -0.35% | -1.01% | |
| Novartis announces plans to build flagship manufacturing hub in North Carolina | Press release | GlobeNewswire | +0.00% | +0.36% | |
| Form 6-K NOVARTIS AG For: Nov 05 | SEC filing · Form 6-K | SEC EDGAR | -0.04% | +0.12% | |
| Form 6-K NOVARTIS AG For: Sep 30 | SEC filing · Form 6-K | SEC EDGAR | -1.04% | -1.67% | |
| Form 6-K NOVARTIS AG For: Oct 27 | SEC filing · Form 6-K | SEC EDGAR | -0.19% | +0.80% | |
| Form 6-K NOVARTIS AG For: Sep 30 | SEC filing · Form 6-K | SEC EDGAR | +0.01% | +2.04% | |
| Argo Biopharma Announces Multi-Asset License and Option Agreements with Novartis for Novel Molecules for Cardiovascular Diseases | Press release | PR Newswire | +0.50% | +1.00% | |
| Leqvio® advances toward broader access with agreement between Novartis and the pan-Canadian Pharmaceutical Alliance | Press release | Canada Newswire | +0.10% | +0.10% | |
| Form 6-K NOVARTIS AG For: Aug 11 | SEC filing · Form 6-K | SEC EDGAR | +0.29% | — | |
| Novartis announces both ianalumab Phase III clinical trials met primary endpoint in patients with Sjögren's disease | Press release | PR Newswire | +0.56% | +0.47% | |
| Novartis twice-yearly* Leqvio® (inclisiran) receives FDA approval for new indication enabling first-line use | Press release | PR Newswire | +0.32% | +2.19% |
Each reaction is the move the market actually made, measured from the news timestamp. Headlines link through to the NVS section they belong to.
Where else NVS is measured.
NVS earnings → · Analyst actions → · SEC filings →
Other Healthcare names, measured the same way
| Ticker | Events | Median 30-min | % positive |
|---|---|---|---|
| IQVIA Holdings, Inc. (IQV) | 329 | +0.02% | 51% |
| DBV Technologies S.A. - American Depositary Shares (DBVT) | 327 | -0.15% | 40% |
| Theravance Biopharma, Inc. - Ordinary Shares (TBPH) | 326 | +0.10% | 57% |
| Verona Pharma plc - American Depositary Shares (VRNA) | 325 | -0.03% | 39% |
Same sector, same measurement: percent move vs. the price at the news timestamp, read at 30 minutes. Sample sizes differ, so the medians are comparable but the confidence behind them is not.
All Healthcare names, measured the same way →
Every ticker we measure the same way24
Apple (AAPL)
How AAPL actually reacts to news, measured.
NVIDIA (NVDA)
How NVDA actually reacts to news, measured.
Tesla (TSLA)
How TSLA actually reacts to news, measured.
Microsoft (MSFT)
How MSFT actually reacts to news, measured.
Advanced Micro Devices (AMD)
How AMD actually reacts to news, measured.
Amazon (AMZN)
How AMZN actually reacts to news, measured.
Alphabet (GOOG)
How GOOG actually reacts to news, measured.
Meta Platforms (META)
How META actually reacts to news, measured.
Broadcom (AVGO)
How AVGO actually reacts to news, measured.
JPMorgan Chase (JPM)
How JPM actually reacts to news, measured.
Visa (V)
How V actually reacts to news, measured.
Walmart (WMT)
How WMT actually reacts to news, measured.
Eli Lilly (LLY)
How LLY actually reacts to news, measured.
UnitedHealth Group (UNH)
How UNH actually reacts to news, measured.
Netflix (NFLX)
How NFLX actually reacts to news, measured.
Johnson & Johnson (JNJ)
How JNJ actually reacts to news, measured.
Exxon Mobil (XOM)
How XOM actually reacts to news, measured.
Home Depot (HD)
How HD actually reacts to news, measured.
Costco (COST)
How COST actually reacts to news, measured.
Mastercard (MA)
How MA actually reacts to news, measured.
Oracle (ORCL)
How ORCL actually reacts to news, measured.
Salesforce (CRM)
How CRM actually reacts to news, measured.
Bank of America (BAC)
How BAC actually reacts to news, measured.
Coca-Cola (KO)
How KO actually reacts to news, measured.
Walt Disney (DIS)
How DIS actually reacts to news, measured.
Browse all tickers
Every name we’ve measured, in one place.
How the numbers are made.
How is Novartis AG's median reaction calculated?
Every labeled NVS news event is measured from its own timestamp: the last trade before the news is the base price, and the move is read at fixed horizons — 30 minutes of trading, then the close. The median across 326 events is what this page reports. Point-in-time, zero look-ahead: no event borrows information from a later one.
What counts as a positive reaction?
Any event whose price move is above zero at the horizon, relative to the last trade before the news timestamp. 51% of NVS's measured events are up at 30 minutes; the rest close the window flat or negative.
How often is this page updated?
The news table refreshes automatically as new events are labeled and priced. The reaction medians are re-pulled in batches from the dataset — the figures here are as of 2026-09-21.
Does NVS's past reaction predict its next one?
No. These are realized facts about past events, not forecasts. They describe a distribution — they say nothing certain about any future move.